PMID- 37025426
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230411
IS  - 2391-5463 (Print)
IS  - 2391-5463 (Electronic)
VI  - 18
IP  - 1
DP  - 2023
TI  - Efficacy of bronchoscopic intratumoral injection of endostar and cisplatin in 
      lung squamous cell carcinoma patients underwent conventional chemoradiotherapy.
PG  - 20230640
LID - 10.1515/med-2023-0640 [doi]
LID - 20230640
AB  - Bronchoscopy has been widely used for the therapy of lung cancer. This study 
      aimed to evaluate the therapeutic efficacy and adverse reactions of bronchoscopic 
      intratumoral injection of endostar and cisplatin in patients with lung squamous 
      cell carcinoma (LSCC). A total of 40 LSCC patients who underwent conventional 
      chemoradiotherapy were included in this study, and 20 of them received a 
      bronchoscopic injection of endostar and cisplatin as an additive therapeutic 
      modality (treatment group). The clinical response rate, progression-free survival 
      (PFS), and adverse reactions of the patients were compared and analyzed. The 
      treatment group had better short- and long-term therapeutic efficacy compared to 
      the control group, but no significant differences were observed between the two 
      therapeutic regimens in adverse reactions. Elderly and advanced LSCC patients had 
      worse therapeutic efficacy and a high probability of adverse reactions after the 
      therapy. Collectively, our analysis data demonstrated that the bronchoscopic 
      intratumoral injection of endostar and cisplatin had improved therapeutic 
      efficacy, and the cardiovascular adverse reactions were within the controllable 
      range in the treatment of LSCC in clinical practices.
CI  - (c) 2023 the author(s), published by De Gruyter.
FAU - Ji, Yanzhen
AU  - Ji Y
AD  - Otorhinolaryngological Department, Hiser Medical Center of Qingdao, Qingdao 
      266033, Shandong, China.
FAU - Luan, Shuli
AU  - Luan S
AD  - Department of Geriatrics, Hiser Medical Center of Qingdao, Qingdao 266033, 
      Shandong, China.
FAU - Yang, Xiaoping
AU  - Yang X
AD  - Pneumology Department, Hiser Medical Center of Qingdao, Qingdao 266033, Shandong, 
      China.
FAU - Yin, Bin
AU  - Yin B
AD  - Pneumology Department, Hiser Medical Center of Qingdao, Qingdao 266033, Shandong, 
      China.
FAU - Jin, Xiaojie
AU  - Jin X
AD  - Pneumology Department, Hiser Medical Center of Qingdao, Qingdao 266033, Shandong, 
      China.
FAU - Wang, Haiyan
AU  - Wang H
AD  - Pneumology Department, Hiser Medical Center of Qingdao, Qingdao 266033, Shandong, 
      China.
FAU - Jiang, Wenqing
AU  - Jiang W
AD  - Pneumology Department, Hiser Medical Center of Qingdao, No. 4 Renmin Road, 
      Qingdao 266033, Shandong, China.
LA  - eng
PT  - Journal Article
DEP - 20230403
PL  - Poland
TA  - Open Med (Wars)
JT  - Open medicine (Warsaw, Poland)
JID - 101672167
PMC - PMC10071812
OTO - NOTNLM
OT  - adverse reactions
OT  - bronchoscopy
OT  - cisplatin
OT  - efficacy
OT  - endostar
OT  - lung squamous cell carcinoma
COIS- Conflict of interest: The authors declare that they have no competing interest.
EDAT- 2023/04/08 06:00
MHDA- 2023/04/08 06:01
PMCR- 2023/04/03
CRDT- 2023/04/07 02:29
PHST- 2022/03/29 00:00 [received]
PHST- 2022/11/20 00:00 [revised]
PHST- 2022/12/22 00:00 [accepted]
PHST- 2023/04/08 06:01 [medline]
PHST- 2023/04/07 02:29 [entrez]
PHST- 2023/04/08 06:00 [pubmed]
PHST- 2023/04/03 00:00 [pmc-release]
AID - med-2023-0640 [pii]
AID - 10.1515/med-2023-0640 [doi]
PST - epublish
SO  - Open Med (Wars). 2023 Apr 3;18(1):20230640. doi: 10.1515/med-2023-0640. 
      eCollection 2023.